The Queen Elizabeth Hospital
Welcome,         Profile    Billing    Logout  
 2 Trials 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Craddock, Charles F
AMADEUS, NCT04173533 / 2018-001012-30: Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT

Active, not recruiting
3
326
Europe
Oral azacitidine, CC-486, Matched placebo, Oral azacitidine matched placebo
University of Birmingham
Acute Myeloid Leukemia, Myelodysplasia
04/25
04/25
COSI, NCT04217278: A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT

Active, not recruiting
2/3
333
Europe
Vyxeos, CPX-351, Fludarabine, Fludara, Busulphan, Busulfan, Bulsivex, Thiotepa, Tepadina, Cytarabine, Ara-C, Cytosine arabinoside
University of Birmingham, Jazz Pharmaceuticals, IMPACT (funded by NHS Blood & Transplant, Anthony Nolan and Leukaemia UK), Adienne SA
Acute Myeloid Leukaemia, High-risk Myelodysplastic Syndrome
03/25
03/25
Kalla, Manish
WEAR-TECH ECG, NCT05298553: Diagnostic Accuracy of WEARable TECHnology Single-lead ECG in Detecting Cardiac Arrhythmias

Completed
N/A
500
Europe
Group A, Group B
Oxford University Hospitals NHS Trust, University Hospital Birmingham, University Hospital Southampton NHS Foundation Trust
Cardiac Arrhythmia, Atrial Fibrillation
04/23
04/23
IMPACT II, NCT04577859: Esophageal Protection Study: A Multicenter Study

Active, not recruiting
N/A
152
Europe, US
ensoETM. Esophageal cooling during AF ablation, Esophageal temperature monitoring probe
Advanced Cooling Therapy, Inc., d/b/a Attune Medical, University of Pennsylvania, Berry Consultants, Texas Cardiac Arrhythmia Research Foundation, Beth Israel Deaconess Medical Center, Kansas City Cardiac Arrhythmia Research LLC
AF - Atrial Fibrillation, Complication, Atrio-Esophageal Fistula
05/26
05/26
GOAL-AF, NCT05221229: Outcome of Overweight AF Patients Following Ablation With a Potential Weight Loss Medication ( )

Active, not recruiting
N/A
29
Europe
Liraglutide plus upstream risk factors modification advice and consultation
University Hospital Birmingham, University of Birmingham
Atrial Fibrillation, Recurrence, Overweight and Obesity, Liraglutide
06/25
06/26
Gatz, Susanne
CRUKD/21/004, NCT05722886: DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Recruiting
2/3
825
Europe
Alectinib, Alecensa, Atezolizumab, Tecentriq, Entrectinib, Rozlytrek, Trastuzumab in combination with pertuzumab, Herceptin in combination with Perjeta, Vemurafenib in combination with cobimetinib, Zelboraf in combination with Cotellic
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy
10/29
10/29
DETERMINE, NCT05786716: Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations

Recruiting
2/3
30
Europe
Trastuzumab, Herceptin, Pertuzumab, Perjeta
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Colorectal Neoplasms, Urinary Bladder Neoplasm, Gallbladder Neoplasms, Salivary Gland Neoplasm, Lung Neoplasm, Pancreatic Neoplasm, Ovarian Neoplasms, Prostatic Neoplasm, Skin Neoplasm
10/29
10/29
DETERMINE, NCT05770102: Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

Recruiting
2/3
30
Europe
Atezolizumab, Tecentriq
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Colorectal Neoplasms, Endometrial Neoplasms, Melanoma
10/29
10/29
DETERMINE, NCT05770037: Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers

Recruiting
2/3
30
Europe
Alectinib, Alecensa
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Anaplastic Large Cell Lymphoma, Lymphoma, Renal Cell Carcinoma, Neuroblastoma
10/29
10/29
DETERMINE, NCT05770544: Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers.

Recruiting
2/3
30
Europe
Entrectinib, Rozlytrek
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Brain Neoplasms, Melanoma, Glioma
10/29
10/29
ESMART, NCT02813135 / 2016-000133-40: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

Recruiting
1/2
455
Europe
Ribociclib, Kisqali, LEE011, Topotecan, Hycamtin, Temozolomide, Temodar, Everolimus, Afinitor, votubia, Adavosertib, AZD1775, Carboplatin, Paraplatin, Olaparib, Lynparza, Irinotecan, Camptosar, CPT-11, Vistusertib, AZD2014, Nivolumab, Opdivo, Cyclophosphamide, Cytoxan, Selumetinib, Koselugo, Enasidenib, Idhifa, Lirilumab, BMS-986015, Fadraciclib, CYC065, Cytarabine, Arabinosylcytosine, Cytosar-U, Dexamethasone, Decadron, Dexasone, Diodex, Hexadrol, Maxidex, Ceralasertib, AZD6738, Futibatinib, Tas-120, Capmatinib, Tabrecta, INC280, Avelumab, BAVENCIO, Peposertib
Gustave Roussy, Cancer Campus, Grand Paris, National Cancer Institute, France
Pediatric Cancer
02/31
02/31
FaR-RMS, NCT04625907 / 2018-000515-24: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

Recruiting
1/2
1672
Europe, RoW
Irinotecan, Actinomycin D, Dactinomycin, Doxorubicin, Ifosfamide, Vincristine, Vinorelbine, Cyclophosphamide, Temozolomide, radiotherapy, Regorafenib
University of Birmingham
Rhabdomyosarcoma
06/30
06/30
Jafri, Mariam
FaR-RMS, NCT04625907 / 2018-000515-24: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

Recruiting
1/2
1672
Europe, RoW
Irinotecan, Actinomycin D, Dactinomycin, Doxorubicin, Ifosfamide, Vincristine, Vinorelbine, Cyclophosphamide, Temozolomide, radiotherapy, Regorafenib
University of Birmingham
Rhabdomyosarcoma
06/30
06/30
Locke, Andrew
IMPACT II, NCT04577859: Esophageal Protection Study: A Multicenter Study

Active, not recruiting
N/A
152
Europe, US
ensoETM. Esophageal cooling during AF ablation, Esophageal temperature monitoring probe
Advanced Cooling Therapy, Inc., d/b/a Attune Medical, University of Pennsylvania, Berry Consultants, Texas Cardiac Arrhythmia Research Foundation, Beth Israel Deaconess Medical Center, Kansas City Cardiac Arrhythmia Research LLC
AF - Atrial Fibrillation, Complication, Atrio-Esophageal Fistula
05/26
05/26

Download Options